NCT06028984进行中（未招募）不适用
Self-guided Treatment for Adolescents/Adults Navigating Depression (STAND-MDD): A Randomized Controlled Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 248
- 试验地点
- 2
- 主要终点
- Patient Health Questionnaire (PHQ-8)
研究概览
简要总结
This study will examine the efficacy and safety of a self-guided digital therapeutic app for the adjunct treatment of Major Depressive Disorder compared to a control app in adolescents and adults.
详细描述
This study aims to examine the efficacy of a self-guided digital therapeutic app for depression compared to a control app in individuals aged 13 and older with a diagnosis of Major Depressive Disorder. The primary outcomes are patient- and clinician-reported depression symptom severity after 5 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Positive self report screen for depression
- •Participant is at least 13 years of age
- •Willing and able to provide informed consent; if under 18 years of age, willing and able to provide assent, and has a legal guardian willing and able to provide consent
- •Primary diagnosis of Major Depressive Disorder (MDD)
- •Under the care of a United States (U.S.)-based licensed healthcare provider and willing and able to provide contact information for the provider and sign a HIPAA release that allows investigator to contact provider
- •Fluent and literate in English
- •Has access to a compatible device and operating system (i.e., capable of installing the app from the Google Play or Apple App Store) and regular internet access
- •Located in the continental U.S., Hawaii, or Alaska, and not planning to leave the U.S. during the primary study period
排除标准
- •Has changed or initiated psychotherapy with a mental health professional within 30 days prior to eligibility screening
- •Has received certain types of psychotherapy within the last 6 months
- •Has changed prescribed psychotropic medication (initiation or change in dose) within the past 30 days
- •Plans to initiate or change treatment (e.g., psychotherapy, psychotropic medication, and/or other psychosocial treatment) for a mental health disorder during study intervention period
- •Suicidal behavior within the past year
- •Active suicide ideation with intent within the past 3 months
- •Previously participated in user testing or a clinical study at Limbix Health Inc. or Big Health Inc. (such as the STAND study or Rise study), or have used a Limbix app
- •Participated in any other clinical research involving an intervention or treatment within the past 60 days
- •Plans to participate in any other clinical research involving an intervention or treatment during the study intervention period
- •Living in the same household as another participant in the study (e.g., a sibling)
- •Has a diagnosis of MDD with psychotic features or comorbid Psychotic Disorder
- •Has a concurrent diagnosis of (or has been treated for) bipolar disorder I and II or severe substance use disorder within the past year
- •Has treatment resistant depression
- •Is employed by Big Health Inc., or is a collaborator, associate, or relation of Big Health Inc. staff
- •Any condition, comorbidity, or event (other than the above) that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the intervention, or will prevent investigators from being able to ensure safety
结局指标
主要结局
Patient Health Questionnaire (PHQ-8)
时间窗: 5 weeks post-randomization
Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity
Montgomery-Åsberg Depression Rating Scale (MADRS)
时间窗: 5 weeks post-randomization
Validated assessment: a 10-item scale based on clinical interview with total scores between 0 and 60 where higher scores indicate greater severity
次要结局
- Response based on the Patient Health Questionnaire (PHQ-8)(5 weeks post-randomization, 1-month followup)
- Remission based on the Patient Health Questionnaire (PHQ-8)(5 weeks post-randomization, 1-month followup)
- Global improvement assessed using the clinician-rated Clinical Global Impression Scale - Improvement (CGI-I)(5 weeks post-randomization, 1-month followup)
- Clinical Global Impression - Severity (CGI-S)(5-weeks post-randomization, 1-month followup)
- Clinically important improvement based on the Montgomery-Åsberg Depression Scale (MADRS)(5 weeks post-randomization, 1-month followup)
- Clinically important improvement based on the Patient Health Questionnaire (PHQ-8)(5 weeks post-randomization, 1-month followup)
- Depression severity assessed with the Patient Health Questionnaire (PHQ-8) at followup(1-, 3- and 6-month followup)
- Clinician-rated depression severity as measured by the Montgomery-Åsberg Depression Scale (MADRS) at followup(1 month follow up)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Self-guided Treatment for Adolescents Navigating DepressionDepressive SymptomsDepressive DisorderDepressive EpisodeDepressionNCT05462652Limbix Health, Inc.223
Unknown
不适用
Efficacy of an App-based CBT Featuring Virtual Reality for Anxiety DisordersSocial PhobiaAgoraphobiaAnxietyPanic DisorderNCT05510804Bartosz of Zurowski222
已完成
不适用
The Young Adult Clinic (YAC) StudyChronic PainInsomniaInsomnia Due to Medical ConditionNCT05147974Women's College Hospital40
已完成
不适用
Digital Mental Health Intervention for Nonsuicidal Self-Injury in Young AdultsNonsuicidal Self InjuryDepressionAnxietySuicidal IdeationNCT05325944Northwestern University90
招募中
不适用
Effectiveness of a Digital Application for Adolescents With Mild to Moderate AnxietyAnxiety and FearAdolescent - Emotional ProblemAnxietyNCT06531980Haukeland University Hospital128